Product Description
MK 3577 is an orally active glucagon receptor antagonist which was under development by Merck & Co for the treatment of type 2 diabetes mellitus. MK 3577 demonstrate activity in cellular models and preclinical trials.Ê (Sourced from: https://drugs.ncats.io/substance/03TW1410NL)
Mechanisms of Action: GcGr Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2009-009517-18 |
2009-009517-18 | P2 |
Terminated |
Type 2 Diabetes |
2010-07-12 |
2022-03-13 |
Treatments |
|
NCT00868790 |
MK-3577-009 | P2 |
Terminated |
Type 2 Diabetes |
2010-07-12 |
2022-05-04 |
Recent News Events
Date |
Type |
Title |
|---|